Parkinson disease (PD [MIM 168600]) affects 1% of individuals older than 65 years. Patients develop both motor and nonmotor symptoms and suffer an inexorable decline in function. Dopaminergic therapies provide temporary relief but are not without side-effects and do not slow disease progression. 1 About 14% of patients with PD report one or more first-degree relatives with parkinsonism. 2 Studies of familial parkinsonism have identified pathogenic mutations in several genes, and such identifications have provided mechanistic insight and novel targets for therapeutic intervention. 3 These loci have been associated with idiopathic PD, emphasizing the importance of studying monogenic forms of disease (see the PDGene database in the Web Resources and Nalls et al. 4 ).
All Mendelian forms of parkinsonism have been identified through classic linkage and Sanger sequence analysis. 3 This study describes NGS applied to a multi-incident Swiss family with autosomal-dominant, late-onset PD (CH; Figure 1 ). The clinical features of this kindred, which includes eleven individuals with a diagnosis of PD, were previously described. 5 DNA samples from six affected and 16 unaffected individuals excluded point mutations and copy-number variants (CNVs) in genes previously implicated in monogenic parkinsonism. 5 To identify the novel pathogenic mutation causing PD in this Swiss kindred, we performed exome sequencing analysis in an affected pair of first-degree cousins ( Figure 1 ). The capture of exonic regions and the subsequent sequencing and characterization of variants was performed by Knome, Inc. NimbleGen Sequence Capture Arrays were used for isolating the genomic coding regions to be sequenced. The NimbleGen Arrays, which contain 2.1 million probes that capture~180,000 exons and~550 miRNA, were used for interrogation of genomic regions from CH III-2 and III-13. Sequencing was subsequently performed on an Illumina Genome Analyzer by 76 bp paired-end reads. The mean coverage per targeted base was 51.6-fold for III-2 and 43.8-fold for III-13, and 73.2% and 60.7% of bases, respectively, had R20-fold coverage. The percentage of targeted bases covered was 98.5% and 97.0% for III-2 and III-13, respectively. Adaptor sequences from reads were filtered via a local dynamic programming algorithm. Reads with more than 12 bp of overlap with adaptor sequences were deemed contaminated and removed; only those reads of 30 bp or longer were used for further analysis. Reads with more than six missing bases or 40 consecutive identical bases were omitted from further processing. The remaining sequences were aligned to a reference sequence (Hg18, build 36.1) with SOAPaligner (parameters -a -D -o -r 1 -t -c -f 4), followed by SOAPsnp so that consensus and call genotypes (parameters -i -d -o -r 0.00005 -e 0.0001 -M -t -u -L -s À2 -T) could be assembled. Validation of common SNP genotypes was conducted against dbSNP v129. Structural variations were determined by the paired-end method and clustering algorithm alignment against CNVs in the Database of Genomic Variants v6 (November 2008) . This analysis identified We recognize that next-generation capture and sequencing methods are limited in coverage and that some bioinformatics results might be erroneous. Thus, we used Sanger sequencing of these novel variants in one sample used for NGS (III-2), two additional affected family members (III-6 and III-9), and one unaffected spouse (II-2) to assess the accuracy of NGS genotype calls and segregation with disease. Thirty-six variants were an artifact; they could not be confirmed by Sanger sequencing and appeared to be a consequence of misaligned repeat sequences. Thirty-three variants were validated, and six were present in family members with PD but not observed in the spouse (Table S1) Figure 1 ). Additional support for variants in chromosomal region 16p12.1-q12.1 is provided by linkage data ( Figure S1 ).
Both variants were subsequently genotyped in a multiethnic case-control series consisting of 4,326 patients and 3,309 controls. This series comprises eight independent PD series from the US, Canada, Norway, Poland, Ireland, Tunisia, Taiwan, and Israel (Yemenite Jews). The demographics for each series are presented in Table S2 . All patients were examined and observed longitudinally by a movement-disorders neurologist and diagnosed with PD according to published criteria. 7 Patients and unrelated controls of identical ethnicity but without evidence of neurological disease were consecutively selected. The ethical review boards at each institution approved the study, and all participants provided informed consent. A combination of Sequenom MassArray iPLEX (San Diego, CA) and TaqMan probes was used for genotyping, and all mutations were confirmed by direct sequencing. Four patients (three familial and one sporadic) and no controls were identified as having VPS35 p.Asp620Asn; in those three families, a total of nine affected individuals are present and carry the mutation (Figure 1 ). In contrast, the ITGAX p.Ala1012Val mutation was found in one control (61 years) and one familial case (42 years at onset), but no other samples were available to allow segregation to be examined. Carrier frequencies for both variants are provided in Table S3 . This data indicate that VPS35 p.Asp620Asn is a pathogenic mutation, whereas ITGAX p.Ala1012Val is a rare variant. VPS35 is highly conserved from humans to yeast, supporting the pathogenicity of the p.Asp620Asn substitution (Figure 2 ), whereas ITGAX is not evolutionarily conserved. Additionally, p.Asp620Asn is an acidic-to-basic change and is predicted to be a deleterious substitution (SIFT score ¼ 0), whereas p.Ala1012Val is not (SIFT score ¼ 0.16). Haplotype analysis of VPS35 p.Asp620Asn was performed with microsatellite markers between D16S401 and D16S3044 (Table 1) . One primer of each pair was labeled with a fluorescent tag; sequences for novel markers are provided in Table S4 . Polymerase chain reactions (PCRs) were performed under standard conditions, and products were run on an ABI 3730 genetic analyzer. Results were analyzed with GeneMapper 4.0 software (Applied Biosystems). Genotyping of VPS35 kindreds shows that the p.Asp620Asn substitution is a mutational hotspot; it has arisen independently from at least four separate mutational events (Table 1) . Only two haplotypes (CH and YE-2) share alleles for an adjacent microsatellite marker (Chr16_45.333M). Interestingly, p.Asp620Asn in two families that share similar ethnicity does not appear to be identical by descent (YE-1 and YE-2).
The average age at disease onset for the CH kindred is 50.6 5 7.3 years (range 42-64 years) and is comparable to 48.3 5 8.6 years (range 40-64 years), the mean age of onset for other families affected by VPS35 p.Asp620Asn. However, the mutation has incomplete, age-associated penetrance; among these pedigrees, there are four unaffected mutation carriers who were between 49 and 67 years at the time of exam (data not shown).
In an attempt to identify novel mutations, we sequenced all 17 VPS35 exons in 190 multiethnic familial probands from the US, Canada, Norway, Poland, Ireland, Tunisia, Taiwan, Israel (Yemenite Jews), France, Switzerland, and Sweden. The ethical review boards at each institution approved the study, and all participants provided informed consent. Primer pairs used for sequencing VPS35 exons and exon-intron boundaries by PCR are provided in Table S4 . PCR products were purified from unincorporated nucleotides via Agencourt bead technology (Beverly, MA) with Biomek FX automation (Beckman Coulter, Fullerton, CA). Sequence analysis was performed as previously described. 8 Sequencing of 106 US probands identified two novel variants, one silent (c.945A>T; p.Gly315Gly) and one missense (c.946C>T; p.Pro316Ser). The age at disease onset for the patients with these variants was 65 and 52 years, respectively. In 22 Tunisian probands, one Figure 1) , and both subjects were carriers; one was diagnosed with PD at 54 years, and the other displayed hand tremor and micrographia at 67 years but did not fulfill the clinical criteria for PD. To further discern the pathogenicity of this variant, we genotyped c.946C>T (p.Pro316Ser) in a multi-ethnic case-control series consisting of 4,326 patients and 3,309 controls (Table S2) . One Norwegian control subject (86 years) with the mutation was identified. Thus, the genetic evidence for the pathogenicity of p.Pro316Ser is inconclusive. However, the high level of species conservation suggests an important functional role (Figure 2 ). Additional studies are required if we are to determine whether p.Pro316Ser is a pathogenic mutation, a risk factor, or a neutral polymorphism.
We also evaluated VPS35 CNVs as a cause of disease in the 190 familial probands previously described. We used two genomic probes against exon 6 and exon 15 of VPS35 and two endogenous control assays against exon 5 of PSEN2 [MIM 600759] and exon 5 of SNCA [MIM 162890] to identify whole-gene CNVs. All primers and probes were purchased from Applied Biosystems, and sequences are available on request. Quantitative PCR was carried out with the TaqMan expression chemistry protocol, 25 ng genomic DNA was amplified with 0.25 ml primer probe and 2.5 ml TaqMan Genes linked to familial parkinsonism have highlighted loci associated with idiopathic PD. Using published genome-wide association study (GWAS) datasets, 9-11 we examined evidence for disease association with VPS35 observed no such evidence (p values ¼ 0.1-0.9; Table S5 ). Nevertheless, coverage of VPS35 was limited, and a lack of association should not preclude more detailed study in ethnically diverse populations. VPS35 is a critical component of the retromer cargorecognition complex, which is involved in the recycling of membrane proteins between endosomes and the transGolgi network. 12, 13 In mammals the pentameric assembly includes the recognition complex of VPS35, VPS29 Figure S2 ). However, VPS35 is known to directly associate The retromer plays a central and intermediate role in recycling of membrane-associated proteins and endosomal-lysosomal trafficking. VPS35 mutations provide a mechanistic tool for exploring dominant-negative versus toxic gain of function and will allow the generation of in vitro and in vivo systems that address whether gene expression or transport of specific cargos explains the selective vulnerability of dopaminergic neurons. Endosomal trafficking appears to be a common pathway disrupted in neurodegenerative diseases. Screening of VPS35 and its interacting partners, not only in PD but also in other movement and cognitive disorders, is warranted if we are to fully understand the role of the retromer in disease development.
Supplemental Data
Supplemental Data include two figures and five tables and can be found with this article online at http://www.cell.com/AJHG/.
